

FORM PTO 1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DKT NO. T103 1530.1	SERIAL NO. 10/607,930
	APPLICANT Bhatti, <i>et al.</i>	
	FILING DATE 06-27-03	GROUP 1614

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CL.	SUBCL.	FILING DATE IF APPROP.
<i>RD</i>	P1	US 2003/ 0171359A1		Dahmann, <i>et al.</i>			16 Oct. 2002

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CL.	SUBCL	TRANSLATION	
							YES	NO
<i>RD</i>	F1	EP 0 970 957 A1	12 Jan 2000					
<i>RD</i>	F2	GB 2 142 332 A	16 Jan 1985					
<i>RD</i>	F3	WO 01/30780 A2 and A3	3 May 2001					
<i>RD</i>	F4	WO 01/66546 A1	13 Sept. 2001					

OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.)

<i>RD</i>	D1	Mukund, M. M., <i>et al.</i> , "Spirocyclic Nonpeptide Glycoprotein IIb-IIIa Antagonists. Part 3: Synthesis and SAR of Potent and Specific 2,8-Diazaspiro[4.5]decanes," <i>Bioorganic & Medicinal Chemistry Letters</i> , 12(7): 1103-1107 (2002).
<i>RD</i>	D2	Smyth, M.S., <i>et al.</i> , "Spirocyclic Nonpeptide Glycoprotein Iib-IIIa Antagonists. Part 1: Design of Potent and Specific 3,9-Diazaspiro [5.5]undecanes," <i>Bioorganic & Medicinal Chemistry Letters</i> , 11(10): 1289-1292 (2001).
<i>RD</i>	D3	PARTIAL INTERNATIONAL SEARCH REPORT (7 November 2003).

EXAMINER <i>RD esar</i>	DATE CONSIDERED <i>9/23/04</i>
----------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE					ATTY DKT NO. T103 1530.1		SERIAL NO. 10/607,930	
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT					APPLICANT Bhatti, <i>et al.</i>			
					FILING DATE 06-27-03		GROUP 1614	
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CL.	SUBCL.	FILING DATE IF APPROP.	
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NO.	DATE	COUNTRY	CL.	SUBCL.	TRANSLATION YES NO	
OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.)								
RD	D1	Mullen, G., <i>et al.</i> , "(–)-Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin-2'-one], a Conformationally Restricted Analogue of Acetylcholine, Is a Highly Selective Full Agonist at the $\alpha 7$ Nicotinic Acetylcholine Receptor," <i>J. Med. Chem.</i> , 43(22): 4045-4050 (2000).						
re	D2	INTERNATIONAL SEARCH REPORT (6 April 2004).						
EXAMINER					DATE CONSIDERED			
RD					9/23/04			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE OCT 28 2003 PATENT & TRADEMARK OFFICE	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DKT NO. T103 1530.1	SERIAL NO. 10/607,930
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
	FILING DATE 06-27-03		GROUP 1614	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CL.	SUBCL.	FILING DATE IF APPROP.
RO	P1	3,282,947	11/1966	Grogan, <i>et al.</i>	260	293	
RO	P2	4,922,901	05/1990	Brooks, <i>et al.</i>	128	203.26	
RO	P3	5,187,166	02/1993	Kikuchi, <i>et al.</i>	514	249	
RO	P4	5,583,140	12/1996	Bencherif, <i>et al.</i>	514	299	
RO	P5	5,597,919	01/1997	Dull, <i>et al.</i>	544	242	
RO	P6	5,604,231	02/1997	Smith, <i>et al.</i>	514	256	
RO	P7	5,616,716	04/1997	Dull, <i>et al.</i>	546	300	
RO	P8	5,663,356	09/1997	Ruecroft, <i>et al.</i>	546	300	
RO	P9	5,672,601	09/1997	Cignarella	514	249	
RO	P10	5,733,912	03/1998	Wasicak, <i>et al.</i>	514	253	
RO	P11	5,852,041	12/1998	Cosford, <i>et al.</i>	514	351	
RO	P12	6,022,868	02/2000	Olesen, <i>et al.</i>	514	210	
RO	P13	US 2003/ 0092700	05/2003	Czollner, <i>et al.</i>	514	217.01	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CL.	SUBCL	TRANSLATION	
							YES	NO
RO	F1	EP 0 297 858	01/1989	EP				
RO	F2	EP 0 360 390	03/1990	EP				
RO	F3	EP 0 417 631	03/1991	EP				
RO	F4	GB 2 295 387	05/1996	GB				
RO	F5	WO 94/08992	4/1994	WO				
RO	F6	WO 96/31475	10/1996	WO				
RO	F7	WO 96/40682	12/1996	WO				
RO	F8	WO 97/40049	10/1997	WO (See published English language related application P13 above)				
RO	F9	WO 98/25619	06/1998	WO				
RO	F10	WO 99/21834	05/1999	WO				

EXAMINER

RO-esar

DATE CONSIDERED

9/23/04


EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



(Form PTO-1449)

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DKT NO. T103 1530.1	SERIAL NO. 10/607,930
<div style="position: absolute; left: -100px; top: 0px; transform: rotate(-90deg); font-size: small;"> RECEIVED OCT 28 2003 PATENT </div>			APPLICANT Bhatti, et al.	
			FILING DATE 06-27-03	GROUP 1614
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				
OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.)				
RO	D1	Abramovitch, R.A., editor, "Pyridine and Its Derivatives," Supp. Part Three, pp. 3-5, in <i>Chemistry of Heterocyclic Compounds</i> , Volume 14 (Interscience Publishers, 1974).		
RO	D2	Adamcik, J.A., and E.J. Miklasiewicz, "Cyanoethylation. I. Weakly Basic Catalysts in the Reaction of Acrylonitrile with Active Methylene Compounds," <i>J. Org. Chem.</i> 28: 336-339 (1963).		
RO	D3	Arneric, S., et al., "Preclinical Pharmacology of ABT-418: A Prototypical Cholinergic Channel Activator for the Potential Treatment of Alzheimer's Disease," <i>CNS Drug Rev.</i> , 1(1): 1-26 (1995).		
RO	D4	Arneric, S.P., et al., "Cholinergic channel modulators as a novel therapeutic strategy for Alzheimer's disease," <i>Exp. Opin. Invest. Drugs</i> , 5(1): 79-100 (1996).		
RO	D5	Bannon, A.W., et al., "Broad-Spectrum, Non-Opioid Analgesic Activity by Selective Modulation of Neuronal Nicotinic Acetylcholine Receptors," <i>Science</i> , 279: 77-81 (1998).		
RO	D6	Bencherif, M., et al., "RJR-2403: A Nicotinic Agonist with CNS Selectivity I: <i>In Vitro</i> Characterization," <i>J. Pharmacol. Exper. Therapeutics</i> , 279(3): 1413-1421 (1996).		
RO	D7	Berkowitz, D.B., and M.K. Smith, "Enantiomerically Enriched α -Methyl Amino Acids. Use of an Acyclic, Chiral Alanine-Derived Dianion with a High Diastereofacial Bias," <i>J. Org. Chem.</i> , 60: 1233-1238 (1995).		
RO	D8	Brioni, J.D., et al., "The Pharmacology of (-)-Nicotine and Novel Cholinergic Channel Modulators," <i>Adv. Pharmacol.</i> , 37: 153-215 (1997).		
RO	D9	Burger, A., et al., "Some Derivatives of Tetrahydropyran as Potential Pharmacodynamic Agents," <i>J. Am. Chem. Soc.</i> , 72: 5512-5515 (1950).		
RO	D10	Cheng, Y., and W.H. Prusoff, "Relationship Between the Inhibition Constant (K_i) and the Concentration of Inhibitor which Causes 50 Per Cent inhibition (I_{50}) of an Enzymatic Reaction," <i>Biochem. Pharmacol.</i> 22(23): 3099-3108 (1973).		
RO	D11	Chiari, A., et al., "Sex Differences in Cholinergic Analgesia I: A Supplemental Nicotinic Mechanism in Normal Females," <i>Anesthesiology</i> , 91(5): 1447-1454 (1999).		
RO	D12	Ciblat, S., et al., "A new route to 2-spiropiperidines," <i>Tet. Lett.</i> , 42: 4815-4817 (2001).		
RO	D13	Clarke, K., and K. Rothwell, "A Kinetic Study of the Effect of Substituents on the Rate of Formation of Alkylpyridinium Halides in Nitromethane Solution," <i>J. Chem. Soc.</i> , 1885-1895 (1960).		
RO	D14	Comins, D.L, and M.O. Killpack, "Lithiation of Methoxypyridines Directed by α -Amino Alkoxides," <i>J. Org. Chem.</i> , 55(1): 69-73 (1990).		
RO	D15	Cosford, N.D.P., et al., "(S)-(-) 5- Ethynyl-3-(1-methyl-2-pyrrolidinyl) pyridine Maleate (SIB-1508Y): A Novel Anti-Parkinsonian Agent with Selectivity for Neuronal Nicotinic Acetylcholine Receptors," <i>J. Med. Chem.</i> , 39(17) : 3235-3237 (1996).		
RO	D16	Culbertson, T.P., et al., "Quinolone Antibacterial Agents Substituted at the 7-Position with Spiroamines. Synthesis and Structure-Activity Relationships," <i>J. Med. Chem.</i> , 33(8): 2270-2275 (1990).		
RO	D17	Damaj, M.I., et al., "Analgesic Activity of Metanicotine, A Selective Nicotinic Agonist," <i>Society for Neuroscience</i> , 23: 669 ABSTRACT 266.9 (1997).		
RO	D18	Damaj, M.I., et al., "Antinociceptive and Pharmacological Effects of Metanicotine, a Selective Nicotinic Agonist," <i>J. Pharmacol. Exp. Ther.</i> , 291(1): 390-398 (1999).		
RO	D19	Decina, P., et al., "Cigarette Smoking and Neuroleptic-Induced Parkinsonism," <i>Biol. Psychiatry</i> , 28(6): 502-508 (1990).		
RO	D20	Elliott, J.M., et al., "Serine Derived NK ₁ Antagonists 2: A Pharmacophore Model for Arylsulfonamide Binding," <i>Bioorg. Med. Chem. Lett.</i> , 8: 1851-1856 (1998).		
RO	D21	Fornicola, R.S., et al., "A New Synthesis of α -Amino Acid Derivatives Employing Methyl Nitroacetate as a Versatile Glycine Template," <i>J. Org. Chem.</i> , 63(11): 3528-3529 (1998).		
RO	D22	Genin, M.J., et al., "Synthesis and Crystal Structure of a Peptidomimetic Containing the (R)-4.4-Spiro Lactam Type-II β -Turn Mimic," <i>J. Org. Chem.</i> , 58(8): 2334-2237 (1993).		
RO	D23	Genin, M.J., and R.L. Johnson, "Design, Synthesis, and Conformational Analysis of a Novel Spiro-Bicyclic System as a Type II β -Turn Peptidomimetic," <i>J. Amer. Chem. Soc.</i> , 114(23): 8778-8783 (1992).		

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DKT NO. T103 1530.1	SERIAL NO. 10/607,930
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Bhatti, et al.	
		FILING DATE 06-27-03	GROUP 1614
D24	Gibson, S., et al., "Principal Components Describing Biological Activities and Molecular Diversity of Heterocyclic Aromatic Ring Fragments," <i>J. Med. Chem.</i> , 39(20): 4065-4072 (1996).		
D25	Grogan, C.H., et al. "Spiranes. VII. Neuroleptics Derived from Azaspiranes," <i>J. Med. Chem.</i> , 8: 62-73 (1965).		
D26	Hall, G.H., and D.M. Turner, "Effects of Nicotine on the Release of ³ H-Noradrenaline from the Hypothalamus," <i>Biochemical Pharmacology</i> , 21: 1829-1838 (1972).		
D27	Hamon, M., "Neuropharmacology of anxiety: perspectives and prospects," <i>TiPS</i> , 15: 36-39 (1994).		
D28	Hansch, C., et al., "The Parabolic Dependence of Drug Action upon Lipophilic Character as Revealed by a Study of Hypnotics," <i>J. Med. Chem.</i> , 11(1): 1-11 (1967).		
D29	Hansch, C., et al., "A Survey of Hammett Substituent Constants and Resonance and Field Parameters," <i>Chem. Rev.</i> , 91(2): 165-195 (1991).		
D30	Hansen, M.M., et al., "An Enantioselective Synthesis of Cis Perhydroisoquinoline LY235959," <i>J. Org. Chem.</i> , 63(3): 775-785 (1998).		
D31	Harsing, Jr., L.G., et al., "Dopamine Efflux from Striatum After Chronic Nicotine: Evidence for Autoreceptor Desensitization," <i>J. Neurochem.</i> , 59(1): 48-54 (1992).		
D32	Hartwig, J.F., et al., "Room-Temperature Palladium-Catalyzed Amination of Aryl Bromides and Chlorides and Extended Scope of Aromatic C-N Bond Formation with a Commercial Ligand," <i>J. Org. Chem.</i> , 64(15): 5575-5580 (1999).		
D33	Hertog, H.J.D., et al., "The Directive Influence of the N-Oxide Group During the Nitration of Derivatives of Pyridine N-Oxide (IV) ¹) Nitration of 3-bromo-5-methoxy- and 3,5-dimethoxy-pyridine-N-oxide ²)," <i>Recueil Trav. Chim. Pays-Bas</i> , 74(8/9): 1171-1179 (1955).		
D34	Hery, F., et al., "Control of the Release of Newly Synthesized ³ H-5-Hydroxytryptamine by Nicotinic and Muscarinic Receptors in Rat Hypothalamic Slices," <i>Naunyn-Schmiedeberg's Arch. Pharmacol.</i> , 296: 91-97 (1977).		
D35	Hinds, M.G., et al., "Synthesis, Conformational Properties, and Antibody Recognition of Peptides Containing β -Turn Mimetics Based on α -Alkylproline Derivatives," <i>J. Med. Chem.</i> , 34(6): 1777-1789 (1991).		
D36	Hoffman, J.M., et al., "Synthesis and Evaluation of 2-Pyridinone Derivatives as HIV-1-Specific Reverse Transcriptase Inhibitors. 4. 3-[2-(Benzoxazol-2-yl)ethyl]-5-ethyl-6-methylpyridin-2(1H)-one and Analogues," <i>J. Med. Chem.</i> , 36(8): 953-966 (1993).		
D37	Holladay, M.W., et al., "Neuronal Nicotinic Acetylcholine Receptors as Targets for Drug Discovery," <i>J. Med. Chem.</i> , 40(26): 4169-4194 (1997).		
D38	Holland, A. et al., "Isothiazoles. Part IX. Isothiazolopyrimidines," <i>J. Chem. Soc.</i> , 7277-7282 (1965).		
D39	Hughes, D.L., "The Mitsunobu Reaction," <i>Org. React.</i> , 42: 335-657 (1992).		
D40	Hughes, D.L., "Progress in the Mitsunobu Reaction. A Review," <i>Org. Prep. Proced. Int.</i> , 28(1): 129-164 (1996).		
D41	Islam, A.M., and R.A. Raphael, "A Direct Transformation of cycloHexanones into bicyclo [5: 3: 0] Dec-7-en-9-ones," <i>J. Chem. Soc.</i> , 3151-3154 (1955).		
D42	Kim, K., et al., "Novel Bicyclic Lactams as XaaPro Type VI β Turn Mimics: Design, Synthesis and Evaluation," <i>J. Org. Chem.</i> , 61(9): 3138-3144 (1996).		
D43	Lall, M.S., et al., "Serine and Threonine β -Lactones: A New Class of Hepatitis A Virus 3C Cysteine Proteinase Inhibitors," <i>J. Org. Chem.</i> , 67(5): 1536-1547 (2002).		
D44	Latli, B., et al., "Novel and Potent 6-Chloro-3-pyridinyl Ligands for the $\alpha 4\beta 2$ Neuronal Nicotinic Acetylcholine Receptor," <i>J. Med. Chem.</i> , 42(12): 2227-2234 (1999).		
D45	Lavand'homme, P., and J.C. Eisenach, "Sex Differences in Cholinergic Analgesia II: Differing Mechanisms in Two Models of Allodynia," <i>Anesthesiology</i> , 91(5): 1455-1461 (1999).		
D46	Lippiello, P.M., et al., "RJR-2403: A Nicotinic Agonist with CNS Selectivity II. <i>In Vivo</i> Characterization," <i>J. P. E. T.</i> , 279(3): 1422-1429 (1996).		
D47	Majer, Z., et al., "Synthesis and Absolute Configuration of 1,7 Diazaspiro[4,4]Nonane-2,6-Dione," <i>Coll. Czech. Chem. Comm.</i> , 47(3): 950-960 (1982).		
D48	Old, D.W., et al., "A Highly Active Catalyst for Palladium-Catalyzed Cross-Coupling Reactions: Room-Temperature Suzuki Couplings and Amination of Unactivated Aryl Chlorides," <i>J. Am. Chem. Soc.</i> , 120(37): 9722-9723 (1998).		

(Form PTO-1449)

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DKT NO. T103 1530.1	SERIAL NO. 10/607,930
		INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
		APPLICANT Bhatti, <i>et al.</i>		FILING DATE 06-27-03	
RO	D49	Onaivi, E.S., <i>et al.</i> , "Chronic Nicotine Reverses Age-Associated Increases in Tail-Flick Latency and Anxiety in Rats," <i>Life Sciences</i> , 54(3): 193-202 (1994).			
RO	D50	Overberger, <i>et al.</i> , "Absolute Configuration of 2,7 Diazaspiro[4.4]nonane. A Reassignment," <i>J. Org. Chem.</i> , 46(13): 2757-2764 (1981).			
RO	D51	Overman, L.E., and R.M. Burk, "A Convenient Synthesis of Unsymmetrical Secondary Amines. <i>In Situ</i> Formation of Unstable Formaldehyde Imines," <i>Tet. Lett.</i> , 25(16): 1635- 1638 (1984).			
RO	D52	Pedersen, M.L., and D.B. Berkowitz, "Formal α -Vinylolation of Amino Acids. Use of a New Benzeneselenolate Equivalent," <i>J. Org. Chem.</i> , 58(25): 6966-6975 (1993).			
RO	D53	Pomerleau, O.F., <i>et al.</i> , "The Effects of Cigarette Smoking on Pain and Anxiety," <i>Addictive Behaviors</i> , 9: 265-271 (1984).			
RO	D54	Pullan, R.D., <i>et al.</i> "Transdermal Nicotine for Active Ulcerative Colitis," <i>New England J. Med.</i> , 330(12): 811-815 (1994).			
RO	D55	Radziszewski, J.G., <i>et al.</i> , "Twisted Si=N Bonds: Matrix Isolation of Bridgehead Silanimines," <i>J. Am. Chem. Soc.</i> , 115(18): 8401-8408 (1993).			
RO	D56	Ranganathan, D., <i>et al.</i> , "Nitroethylene: A Stable, Clean, and Reactive Agent for Organic Synthesis," <i>J. Org. Chem.</i> , 45(7): 1185-1189 (1980).			
RO	D57	Rapier, C., <i>et al.</i> , "Stereoselective Nicotine-Induced Release of Dopamine from Striatal Synaptosomes: Concentration Dependence and Repetitive Stimulation," <i>J. Neurochem.</i> , 50(4): 1123-1130 (1988).			
RO	D58	Reiter, L.A., "Synthesis of 4(5)-Acyl-, 1-Substituted 5-Acyl-, and 1-Substituted 4-Acyl-1H-imidazoles from 4-Aminosioxazoles," <i>J. Org. Chem.</i> , 52(13): 2714-2726 (1987).			
RO	D59	Ricciardi, F.J., and P.H. Doukas, "Facile Synthesis of Styrlquinuclidines," <i>Heterocycles</i> , 24(4): 971-977 (1986).			
RO	D60	Rice, L.M., <i>et al.</i> , "Spiranes. V(1) A Synthetic Route to Symmetrical and Unsymmetrical 3,9-Diazaspiro [5.5] undecanes," <i>J. Het. Chem.</i> , 1(3): 125-127 (1964).			
RO	D61	Rowell, P.P. and D.L. Winkler, "Nicotinic Stimulation of [3 H] Acetylcholine Release from Mouse Cerebral Cortical Synaptosomes," <i>J. Neurochem.</i> , 43(6): 1593-1598 (1984).			
RO	D62	Sanberg, P.R., <i>et al.</i> , "Nicotine Potentiation of Haloperidol-Induced Catalepsy: Striatal Mechanisms," <i>Pharmacol. Biochem. & Behavior</i> , 46: 303-307 (1993).			
RO	D63	Sandor, N.T., <i>et al.</i> "Effect of nicotine on dopaminergic-cholinergic interaction in the striatum," <i>Brain Res.</i> , 567: 313-316 (1991).			
RO	D64	Selnick, H.G., <i>et al.</i> , "Preparation and Trapping of 3-Lithium-O-Lithiophenoxide," <i>Tet. Lett.</i> , 34(13): 2043-2046 (1993).			
RO	D65	Smith, P.W., <i>et al.</i> , "New Spiropiperidines as Potent and Selective Non-Peptide Tachykinin NK ₂ Receptor Antagonists," <i>J. Med. Chem.</i> , 38(19): 3772-3779 (1995).			
RO	D66	Süss, R. and A.G. Sandoz, "Regiospezifische Reduktionen von 1,3,3-trisubstituierten Succinimiden mit Diboran," <i>Helv. Chim. Acta</i> , 60: 1650-1656 (1977).			
RO	D67	Sury, E., and K. Hoffmann, "Über Alkylenimin-Derivate. Beitrag zur Kenntnis der Diaza-spiro-undecane," <i>Helv. Chim. Acta</i> , 36: 1815-1820 (1953).			
RO	D68	Thomas, J. and D. Clough, "The Preparation and Measurement of the Surface Activity of a Series of 4-Alkyl-1,1'-Spirobipiperidinium Bromides," <i>J. Pharm. Pharmacol.</i> , 15(3): 167-177 (1963).			
RO	D69	Toth, E., <i>et al.</i> , "Effect of Nicotine of Extracellular Levels of Neurotransmitters Assessed by Microdialysis in Various Brain Regions: Role of Glutamic Acid," <i>Neurochem. Res.</i> , 17(3): 265-270 (1992).			
RO	D70	Tripathi, H.L., <i>et al.</i> , "Nicotine-Induced Antinociception of Rats and Mice: Correlation with Nicotine Brain Levels," <i>J. Pharmacol. Exp. Ther.</i> , 221(1): 91-96 (1982).			
RO	D71	Vizi, E.S., "Acetylcholine release from guinea-pig ileum by parasympathetic ganglion stimulants and gastrin-like polypeptides," <i>Br. J. Pharmac.</i> , 47: 765-777 (1973).			
RO	D72	Wagaw, S. and S.L. Buchwald, "The Synthesis of Aminopyridines: A Method Employing Palladium-Catalyzed Carbon-Nitrogen Bond Formation," <i>J. Org. Chem.</i> , 61(21): 7240-7241 (1996).			
RO	D73	Wagner, B., <i>et al.</i> , "Does Smoking Reduce the Risk of Neuroleptic Parkinsonoids?," <i>Pharmacopsychiat.</i> , 21: 302-303 (1988).			

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DKT NO. T103 1530.1	SERIAL NO. 10/607,930
 INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Bhatti, <i>et al.</i>	
				FILING DATE 06-27-03	GROUP 1614
	D74	Wittekind, R.R., and C. Weissman, "Synthesis of the 1,8-Diazaspiro [4.5] decane System," <i>J. Het. Chem.</i> , 9(1): 111-113 (1972).			
	D75	Williams, M., <i>et al.</i> , "Neuronal Nicotinic Acetylcholine Receptors," <i>Drug News Perspec.</i> , 7(4): 205-223 (1994).			
	D76	Zhu, J., <i>et al.</i> "Asymmetric Synthesis. 29. Preparation of 1,8-Diazaspiro{5.5} undecane Derivatives," <i>J. Org. Chem.</i> , 58(23): 6451-6456 (1993).			
	D77	Zwart, C., and J.P. Wibaut, "Chemical Behaviour of 3-Aminopyridine and of 3,5-Diaminopyridine. Syntheses of (3-Pyridyl)-Pyrazolones." <i>Recueil Trav. Chim. Pays-Bas</i> , 74(8/9): 1062-1069 (1955).			
	D78	Delphion Printout – Bibliographic Data for EP 0417 631 A2 (Document F3) shows Derwent English language abstract. Oct. 21, 2003.			
EXAMINER				DATE CONSIDERED 9/23/04	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					